Pharmacokinetics of intratumoral RK-28, a new hypoxic radiosensitizer

摘要: Abstract RK-28 is one of the new hypoxic cell radiosensitizers being developed in Japan and has been tested clinically. To reduce its toxicity increase sensitizing activity, intratumoral injection was performed during intraoperative radiation therapy for pancreatic cancer. This report presents results pharmacokinetic studies 10 17 patients who were administrated intravenous or therapy. No adverse effects noted following drug. Pharmacokinetic demonstrated several metabolites both serum tumor tissues. After injection, drug concentration ranged from 123 gg/g to 9,292 μg/g just after (30–50 min compound), while 4.1 9.8 μ/ml. The 23.3 at 45 RK-28. Thus, superior administration this study. combination appears be a feasible treatment method.